The Mutational Landscape of Pancreatic and Liver Cancers, As Represented by Circulating Tumor DNA

Overview

Journal Front Oncol

Specialty Oncology

Date 2019 Oct 15

PMID 31608239

Citations 5

Authors

Alistair Rice

Armando Del Rio Hernandez

Affiliations

Soon will be listed here.

Abstract

The mutational landscapes of pancreatic and liver cancers share many common genetic alterations which drive cancer progression. However, these mutations do not occur in all cases of these diseases, and this tumoral heterogeneity impedes diagnosis, prognosis, and therapeutic development. One minimally invasive method for the evaluation of tumor mutations is the analysis of circulating tumor DNA (ctDNA), released through apoptosis, necrosis, and active secretion by tumor cells into various body fluids. By observing mutations in those genes which promote transformation by controlling the cell cycle and oncogenic signaling pathways, a representation of the mutational profile of the tumor is revealed. The analysis of ctDNA is a promising technique for investigating these two gastrointestinal cancers, as many studies have reported on the accuracy of ctDNA assessment for diagnosis and prognosis using a variety of techniques.

Citing Articles

The Mutation Portraits of Oncogenes and Tumor Supressor Genes in Predicting the Overall Survival in Pancreatic Cancer: A Bayesian Network Meta-Analysis.

Aryanti C, Uwuratuw J, Labeda I, Raharjo W, Lusikooy R, Rauf M Asian Pac J Cancer Prev. 2023; 24(8):2895-2902.

PMID: 37642079 PMC: 10685232. DOI: 10.31557/APJCP.2023.24.8.2895.

Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of Pancreatic Ductal Adenocarcinoma.

Osei-Bordom D, Sachdeva G, Christou N Front Med (Lausanne). 2022; 8:788869.

PMID: 35096878 PMC: 8795626. DOI: 10.3389/fmed.2021.788869.

Circulating mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX.

van der Sijde F, Azmani Z, Besselink M, Bonsing B, de Groot J, Groot Koerkamp B Ther Adv Med Oncol. 2021; 13:17588359211033704.

PMID: 34422118 PMC: 8377319. DOI: 10.1177/17588359211033704.

Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review.

Huerta M, Rosello S, Sabater L, Ferrer A, Tarazona N, Roda D Cancers (Basel). 2021; 13(5).

PMID: 33673558 PMC: 7956845. DOI: 10.3390/cancers13050994.

Molecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma Classification.

Espiau-Romera P, Courtois S, Parejo-Alonso B, Sancho P J Clin Med. 2020; 9(12).

PMID: 33371431 PMC: 7767410. DOI: 10.3390/jcm9124128.

References

Yeo W, Wong N, Wong W, Lai P, Zhong S, Johnson P . High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver Int. 2005; 25(2):266-72. DOI: 10.1111/j.1478-3231.2005.01084.x. View

Rayess H, Wang M, Srivatsan E . Cellular senescence and tumor suppressor gene p16. Int J Cancer. 2011; 130(8):1715-25. PMC: 3288293. DOI: 10.1002/ijc.27316. View

Ng C, Di Costanzo G, Tosti N, Paradiso V, Coto-Llerena M, Roscigno G . Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study. Ann Oncol. 2018; 29(5):1286-1291. DOI: 10.1093/annonc/mdy083. View

Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T . AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet. 2000; 24(3):245-50. DOI: 10.1038/73448. View

Sefrioui D, Blanchard F, Toure E, Basile P, Beaussire L, Dolfus C . Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours. Br J Cancer. 2017; 117(7):1017-1025. PMC: 5625666. DOI: 10.1038/bjc.2017.250. View

Huang A, Zhang X, Zhou S, Cao Y, Huang X, Fan J . Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity. J Cancer. 2016; 7(13):1907-1914. PMC: 5039376. DOI: 10.7150/jca.15823. View

Peters D, Pretorius P . Origin, translocation and destination of extracellular occurring DNA--a new paradigm in genetic behaviour. Clin Chim Acta. 2011; 412(11-12):806-11. DOI: 10.1016/j.cca.2011.01.026. View

Hadano N, Murakami Y, Uemura K, Hashimoto Y, Kondo N, Nakagawa N . Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. Br J Cancer. 2016; 115(1):59-65. PMC: 4931379. DOI: 10.1038/bjc.2016.175. View

Day J, DiGiuseppe J, Yeo C, Anderson S, Goodman S, Kern S . Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol. 1996; 27(2):119-24. DOI: 10.1016/s0046-8177(96)90364-0. View

10.

Rao C, Asch A, Yamada H . Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer. Carcinogenesis. 2016; 38(1):2-11. PMC: 5219050. DOI: 10.1093/carcin/bgw118. View

11.

Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin C . Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol (NY). 2017; 43(1):13-25. DOI: 10.1007/s00261-017-1209-1. View

12.

Tokuhisa Y, Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T . Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. Br J Cancer. 2007; 97(10):1399-403. PMC: 2360234. DOI: 10.1038/sj.bjc.6604034. View

13.

Malkoski S, Wang X . Two sides of the story? Smad4 loss in pancreatic cancer versus head-and-neck cancer. FEBS Lett. 2012; 586(14):1984-92. PMC: 3285395. DOI: 10.1016/j.febslet.2012.01.054. View

14.

Lo Y, Zhang J, Leung T, Lau T, Chang A, Hjelm N . Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet. 1999; 64(1):218-24. PMC: 1377720. DOI: 10.1086/302205. View

15.

Bronkhorst A, Wentzel J, Aucamp J, van Dyk E, du Plessis L, Pretorius P . Characterization of the cell-free DNA released by cultured cancer cells. Biochim Biophys Acta. 2015; 1863(1):157-65. DOI: 10.1016/j.bbamcr.2015.10.022. View

16.

Kang S, Kim B, Han H, Lee J, Kim J, Shim H . Targeted sequencing with enrichment PCR: a novel diagnostic method for the detection of EGFR mutations. Oncotarget. 2015; 6(15):13742-9. PMC: 4537046. DOI: 10.18632/oncotarget.3807. View

17.

Xu H, Zhu X, Xu Z, Hu Y, Bo S, Xing T . Non-invasive Analysis of Genomic Copy Number Variation in Patients with Hepatocellular Carcinoma by Next Generation DNA Sequencing. J Cancer. 2015; 6(3):247-53. PMC: 4317760. DOI: 10.7150/jca.10747. View

18.

Tajadini M, Panjehpour M, Javanmard S . Comparison of SYBR Green and TaqMan methods in quantitative real-time polymerase chain reaction analysis of four adenosine receptor subtypes. Adv Biomed Res. 2014; 3:85. PMC: 3988599. DOI: 10.4103/2277-9175.127998. View

19.

Kirk G, Mendy M, Goedert J, Merle P, Trepo C, Brechot C . Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J Natl Cancer Inst. 2000; 92(2):148-53. DOI: 10.1093/jnci/92.2.148. View

20.

Wang W, Kong P, Ma G, Li L, Zhu J, Xia T . Characterization of the release and biological significance of cell-free DNA from breast cancer cell lines. Oncotarget. 2017; 8(26):43180-43191. PMC: 5522137. DOI: 10.18632/oncotarget.17858. View